Fig. 1 · Structure

Documents & Downloads

Letrozole

Cat. No. A10523 CAS 112809-51-5

Aromatase inhibitor

Letrozole is an Aromatase inhibitor. CGS 20267 is a new non-steroidal compound which potently inhibits aromatase in vitro (IC50 of 11.5 nM) and in vivo (ED50 of 1–3 μg/kg p.o.)

In Stock

Publications for Letrozole

1 publication citing this product

  1. WEI LIU, .et al. , Exp Ther Med, 2015, Oct; 10(4): 1297-1302 PMID: 26622481

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Letrozole inhibits aromatase-dependent estrogen signaling in a cellular reporter model. In MCF-7aro/ERE cells, it suppressed testosterone-driven ERE luciferase activity, while direct estradiol stimulation remained active. This substrate-bypass result supports inhibition upstream of estrogen-receptor activation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Aromatase (Cell-free assay) 0.07 nM-20 nM

Cellular Effect

Cell Line Activity Value Description Reference
BT-549 GI50 0.89 μM Growth inhibition of human BT549 cells after 48 hrs by sulforhodamine B assay [PMID: 20950898]
HeLa GI50 > 100 μM Growth inhibition of non-estrogen-sensitive human HeLa cells after 72 hrs by MTT assay [PMID: 24025069]
Hs-578T GI50 2.17 μM Growth inhibition of human Hs 578T cells after 48 hrs by sulforhodamine B assay [PMID: 20950898]
HT-29 GI50 > 100 μM Growth inhibition of non-estrogen-sensitive human HT-29 cells after 72 hrs by MTT assay [PMID: 24025069]
IGROV-1 GI50 > 100 μM Growth inhibition of estrogen-sensitive human IGROV1 cells after 72 hrs by MTT assay [PMID: 24025069]
IGROV-1 GI50 0.095 μM Growth inhibition of human IGROV1 cells after 48 hrs by sulforhodamine B assay [PMID: 20950898]
JEG-3 IC50 0.89 nM Inhibition of aromatase in human JEG3 cells by scintillation spectrometry [PMID: 20148564]
Jurkat GI50 > 100 μM Growth inhibition of non-estrogen-sensitive human Jurkat cells after 72 hrs by MTT assay [PMID: 24025069]
MCF-10A IC50 > 10 μM Antiproliferative activity against human MCF-10A cells assessed as reduction in cell viability after 72 hrs by cell counter method [PMID: 34364162]
MCF7 GI50 > 100 μM Growth inhibition of estrogen-sensitive human MCF7 cells after 72 hrs by MTT assay [PMID: 24025069]
MCF7 GI50 0.7 μM Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay [PMID: 20950898]
MCF7 IC50 20 nM Cytotoxicity against human MCF7 cells after 24 to 96 hrs [PMID: 24345481]
MCF7 IC50 4.1 μM Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by cell counter method [PMID: 34364162]
MCF7 GI50 4.1 μM Growth inhibition of human MCF7 cells incubated for 72 hrs by cell counting based method [PMID: 30822713]
MCF7 IC50 4.73 μM Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay [PMID: 29202405]
MCF7 IC50 7 nM Cytotoxicity against estrogen-dependent human MCF7 cells after 72 hrs by MTT assay [PMID: 24345481]
MDA-MB-231 GI50 0.15 μM Growth inhibition of human MDA-MB-231cells after 48 hrs by sulforhodamine B assay [PMID: 20950898]
MDA-MB-231 GI50 10 μM Growth inhibition of human MDA-MB-231 cells incubated for 72 hrs by cell counting based method [PMID: 30822713]
MDA-MB-231 GI50 34 μM Growth inhibition of human ER-negative MDA-MB-231 cells incubated for 72 hrs by cell counter method [PMID: 32435378]
MDA-MB-435 GI50 0.067 μM Growth inhibition of human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay [PMID: 20950898]

20 records · Scroll to view more

Letrozole Research Summary

This section summarizes 2 in vitro studies of Letrozole from 2 published references.

Letrozole In Vitro Studies

In MCF-7aro/ERE cells exposed for 24 h, letrozole had a reported 75 nM midpoint for inhibition of the reporter response to 0.1 nM testosterone. The paper labels this value EC50 in its results and table heading, but IC50 in the table caption. It is a functional reporter endpoint and should not be treated as a direct enzyme IC50. [1]

A later AroER tri-screen study reported a letrozole positive-control IC50 of 6.9 ± 1.6 nM (SD) with 0.5 nM testosterone over 24 h. This value belongs to the miniaturized reporter assay; the two reporter studies do not establish interchangeable potency estimates across assay conditions. [2]

Substrate-dependent inhibition of an estrogen-responsive reporter

Cell-based study · ER-positive, aromatase-overexpressing MCF-7aro/ERE human breast cancer cells [1]

Letrozole suppressed testosterone-driven ERE luciferase expression, whereas direct estradiol stimulation bypassed this effect. This is a functional reporter experiment, not a purified-enzyme or proliferation assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of ERE-mediated luciferase activity with 0.1 nM testosteroneReported EC50 (Table caption: IC50) 75 nM[1]
Comparison of testosterone- and estradiol-driven reporter responsesReported qualitative response 400 nM: complete inhibition with 0.1 nM testosterone; no reduction reported with 0.1 nM estradiol[1]

Literature-Reported Treatment Conditions

Treatment concentration
20, 50, 100 and 400 nM letrozole (Figure 3C)
Exposure duration
24 h
Method
Cell-based ERE luciferase assay; phenol red-free MEM with 10% charcoal/dextran-treated FBS; protein normalization.
Vehicle
DMSO
Co-treatment
0.1 nM testosterone or 0.1 nM 17β-estradiol in separate conditions; letrozole alone also examined.
Reported limits
Final DMSO fraction and replicate count/error-bar definition for Figure 3C are not explicitly specified in its caption or shared luciferase methods. Table 1 gives no uncertainty for the midpoint.
Methods and source locations

Compound reported in the paper: Letrozole; Compound label in the paper: Let

Evidence concerns the reported letrozole material; no Adooq product or lot validation.

Sections 2.1, 2.3–2.4, 3.1–3.4; Figure 3C and caption; Table 1; Discussion

Inhibition of ERE-mediated luciferase activity with 0.1 nM testosterone: Luciferase activity normalized to lysate protein and expressed relative to hormone-induced activity after background subtraction. — Table 1, letrozole row; Results 3.4; Methods 2.4

Comparison of testosterone- and estradiol-driven reporter responses: Hormone-only positive controls, DMSO negative control and letrozole-only conditions; Figure 3C viewed. No exact bar values inferred. — Figure 3C and caption; Results 3.4

Letrozole control response in a miniaturized aromatase reporter assay

Cell-based study · AroER tri-screen: ER-positive, aromatase-expressing MCF-7-derived cells with ERE luciferase, 1536-well format [2]

Letrozole served as a positive control in testosterone-stimulated screening. Its assay-specific reporter IC50 was reported with SD; this control result does not measure tumor growth or establish a purified-enzyme IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Half-maximal inhibition of testosterone-stimulated reporter responseIC50 (reported with SD) 6.9 ± 1.6 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Letrozole control titration: 3.2 pM to 46 μM; fixed control wells: 500 nM and 100 nM.
Exposure duration
24 h
Method
Testosterone-stimulated AroER tri-screen; luminescence readout with DMSO and letrozole control normalization.
Vehicle
DMSO
Co-treatment
0.5 nM testosterone
Reported limits
The number of control observations underlying the reported SD is not specified in the selected result. The library was screened three times; this is not assigned as n for the control SD.
Methods and source locations

Compound reported in the paper: Letrozole; Compound label in the paper: Letrozole positive control

Evidence concerns the reported letrozole material; no Adooq product or lot validation.

Materials and Methods: Screen using testosterone (T)-stimulated mode, Tox21 qHTS data analysis; Results: qHTS Performance of AroER Triscreen

Half-maximal inhibition of testosterone-stimulated reporter response: 24-h testosterone-stimulated luciferase assay. The study also used a same-well CellTiter-Fluor viability counterscreen, without reporting a letrozole-specific viability value in this result. — Materials and Methods: Screen using testosterone (T)-stimulated mode, Tox21 qHTS data analysis; Results: qHTS Performance of AroER Triscreen

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 112809-51-5
Applications Aromatase inhibitor
Formula C17H11N5
Molecular Weight 285.3
Synonyms CGS 20267; Femara; Piroxicam
SMILES
C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 50 mg/mL (175.25 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
0.5% CMC Na

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Letrozole Research References

  1. [1] Ki Lui, Takaya Tamura, Taisuke Mori, et al. MCF-7aro/ERE, a Novel Cell Line for Rapid Screening of Aromatase Inhibitors, ERα Ligands and ERRα Ligands Biochemical Pharmacology (2008). PMID: 18550029 DOI: 10.1016/j.bcp.2008.04.011 Source material
  2. [2] Shiuan Chen, Jui-Hua Hsieh, Ruili Huang, et al. Cell-Based High-Throughput Screening for Aromatase Inhibitors in the Tox21 10K Library Toxicological Sciences (2015). PMID: 26141389 DOI: 10.1093/toxsci/kfv141 Source material

Publications

1 publication citing this product

  1. WEI LIU, .et al. , Exp Ther Med, 2015, Oct; 10(4): 1297-1302 PMID: 26622481

Added to your cart

View Cart Checkout
Loading...